Follicle-stimulating hormone (FSH), a pituitary glycoprotein hormone, is an integral component of the endocrine axis that regulates gonadal function and fertility. To transmit its signal, FSH must bind to its receptor (FSHR) located on Sertoli cells of the testis and granulosa cells of the ovary. Thus, both the magnitude and the target of hormone response are controlled by mechanisms that determine FSHR levels and cell-specific expression, which are supported by transcription of its gene. The present review examines the status of FSHR/Fshr gene regulation, emphasizing the importance of distal sequences in FSHR/Fshr transcription, new insights gained from the influx of genomics data and bioinformatics, and emerging trends that offer direction in deciphering the FSHR/Fshr regulatory landscape.
THE GONADOTROPIN HORMONES
Luteinizing hormone (LH) and follicle-stimulating hormone (FSH) are integral parts of the neural and endocrine interchange between the hypothalamus, pituitary, and gonads that controls steroid hormone synthesis and gamete production (for review, see [1] [2] [3] ). At the top of the network is gonadotropin-releasing hormone, which, when released from the hypothalamus, binds receptors on pituitary gonadotrophs and induces the synthesis and secretion of LH and FSH. Once in circulation, LH and FSH finalize the communication by binding to their receptors and transmitting signals to the gonads. These signals are at the hub of the regulatory network, relaying neuronal signals from the hypothalamus to the gonads and inducing feedback signals returned to the hypothalamus and pituitary. The receptors for FSH and LH (FSHR and LHR [LHCGR] , respectively) reside on the surface of somatic cells in the gonads and are members of the Rhodopsin receptor family of G protein-coupled receptors (GPCRs), but unlike the other members, LHR and FSHR have extended NH2-terminal extracellular domains with numerous leucine-rich repeats that assist ligand specificity [4] [5] [6] [7] [8] . FSH binding elicits several diverse signaling events, but the most characterized is that initiated by adenylyl cyclase, followed by induction of cAMP, protein kinase A activation, and protein phosphorylation [9, 10] . FSH binding is also associated with increased intracellular calcium, activation of mitogen-activated protein kinase, and stimulation of inositol triphosphate [11] [12] [13] .
Because FSH acts exclusively through FSHR, mechanisms controlling receptor expression determine the FSH-responsive cell population and influence their sensitivity to hormone. Thus, FSHR expression determines both the targets and the extent of FSH action, ultimately directing hormone response to granulosa cells in the ovary and Sertoli cells in the testis [10] . In the ovarian granulosa cells, temporal changes in FSH signaling regulate a number of transcriptional, metabolic, and hormonal activities that are important for the proliferation and differentiation events required for follicular growth and oocyte maturation [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] . In testicular Sertoli cells, the actions of FSH change with testis development (for review, see [24, 25] ). Initially, during the perinatal period, FSH induces Sertoli cell proliferation and establishes the final Sertoli cell number that will ultimately determine spermatogenic output, whereas later in development, FSH stimulates Sertoli cell transcriptional and metabolic activities, which contribute to the hormonal and nutritional environment necessary for germ cell survival and development [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] . In both males and females, FSH induces hormonal signals that return to the pituitary and hypothalamus as part of the feedback mechanism upholding the endocrine balance in the reproductive axis [36] [37] [38] [39] [40] [41] .
FSHR EXPRESSION
Expression of FSHR, both protein and mRNA, is remarkably limited with respect to its cellular profile, with Sertoli and granulosa cells being the predominant expressing cell types by far [42] [43] [44] [45] . FSHR/Fshr transcripts are first observed in embryonic gonads, around Embryonic Day 14.5 in males and Embryonic Day 20.5 in females [20, 42] . These initial transcripts are incomplete and represent only the extracellular portion of the receptor, with full-length mRNA expressed several days later [20, 46, 47] . In the rodent ovary, Fshr expression coincides with primary follicle formation and follicular development through the preantral stage, with initial full-length transcripts and hormone binding observed shortly after birth (around Postnatal Day 3) and continuing to increase through Postnatal Day 21 [15, 20, [47] [48] [49] . In the testis, fulllength FSHR mRNA initiates during fetal development (around Embryonic Day 16.5 in the rat), and expression is maintained throughout development and in the adult testis [20, 42, 43, 48, [50] [51] [52] [53] . Once the spermatogenic cycle is initiated, FSHR levels change with the cycle, with levels being highest at stages XIII-II and lowest at stages VI-IX [43, [54] [55] [56] . Several signals that regulate ovarian and testicular physiology also influence FSHR expression. In the ovary, FSHR is regulated directly by a combination of transcriptional and posttranscriptional mechanisms induced by FSH and activin and indirectly by follistatin through its influence on activin [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] . In the testis, FSHR is primarily regulated by its ligand, which decreases its expression through several mechanisms, including membrane receptor internalization, mRNA stability, and transcriptional regulation [64, [67] [68] [69] [70] [71] .
Expression of FSHR is considered to be gonad-specific and restricted to Sertoli cells in the testis and granulosa cells in the ovary, but a few notable reports of its presence elsewhere, particularly in the uterus, prostate, bone, and ovarian surface epithelia, have appeared [72] [73] [74] [75] . In prostate and ovarian epithelial cells, FSH signaling is implicated in cell proliferation and tumor invasiveness in precancerous and malignant cells; thus, reports of receptor expression are often within the same cell context [72, [76] [77] [78] . In bone, strong evidence links FSH and FSHR to hypogonadal bone loss in women, but uncertainty remains concerning the site of FSH action [74, [79] [80] [81] [82] . Consequently, it has been difficult to assess from the literature the degree to which normally differentiated cells, other than Sertoli and granulosa cells, actively transcribe FSHR/Fshr. However, its specificity can be greatly appreciated using publically available, high-throughput expression data to examine distribution of FSHR/Fshr mRNA. As an example, data derived from more than 30 tissues using massively parallel signature sequencing (FSHR query with GEO Series accession no. GSE1581 [http://www.ncbi.nlm.nih.gov/geo/query/acc. cgi?acc¼GSE1581] and dataset record GDS868) showed FSHR/Fshr mRNA only in the testis and ovary-a remarkable finding given the high sensitivity of the detection method [83] [84] [85] . The mechanism responsible for this remarkable cell specificity is currently unknown, but as reviewed below, the evidence indicates FSHR/Fshr expression is directed by transcription factors that function through elements located at significant distances from the gene itself.
FSHR/Fshr TRANSCRIPTION
Transcription of FSHR/Fshr contributes to receptor levels and directs its cell specificity, indicating that components of the underlying mechanisms are important for both FSH responsiveness and target cell identity. Our current understanding of FSHR/Fshr transcription is derived largely from studies of the rat, murine, ovine, and human FSHR/Fshr genes, which focused on characterization of the 5 0 flanking region. The resulting data provided significant insight, revealing both similarities and differences between promoters of the four species. Because most promoter characteristics were detailed in a previous review, the discussion here will be limited to its prominent features [86] .
The accumulated information represents primarily transient transfection and DNA/protein binding results from Sertoli and granulosa cells. These studies identified regulatory elements and their associated binding proteins within promoters represented by various species and lengths, and their results revealed both similarities and differences in promoter function [87] [88] [89] [90] [91] [92] [93] [94] [95] [96] [97] . Promoter sequence comparisons between several species showed significant conservation of approximately 1000 bp 5 0 to the translational start, a reference point used to avoid uncertainty in transcriptional start sites for some species [13, 86, 88, 92, [97] [98] [99] . Variations in methodology and promoter context make it hard to assess relevance to regulatory sequences identified in a single species or study, but results representing the rat, sheep, and human promoters show a common E box element [87, 90, 94-97, 100, 101] . This element contributes significantly to promoter activity and provides a common mechanistic theme that features the E box and its cognate binding factors, upstream stimulatory factors (USF1 and USF2) (Fig. 1A) . Other promoter sequences implicated in FSHR/Fshr regulation include binding sites for steroidogenic factor 1 (SF1, official symbol NR5A1), mothers against decapentaplegic homolog 3 (SMAD3), transcription factor E2F, GATA-binding factor 1 (GATA1), and E-twentysix proteins [89, 93, [102] [103] [104] .
Located just 5 0 to the transcriptional start sites, the E box and its binding proteins have received the greatest attention by far with respect to FSHR/Fshr transcription. USF1 and USF2 are members of the helix-loop-helix family that form both homodimers (USF1 and USF2) and heterodimers (USF1/2), and considerable evidence from studies in rodents documents their role directing Fshr promoter activity via the E box [87, 89-91, 100, 105-108] . In both testis and ovary, in vitro (electrophoretic mobility shift assay) and in vivo (chromatin immunoprecipitation [ChIP] ) studies showed USF1, USF2, and USF1/2 bind the promoter, but dimer composition differed between males and females, with USF1/2 and USF1 favored in the testis and USF1, USF2, and USF1/2 equally matched in the ovary (Fig. 1B) [109] . Furthermore, Fshr mRNA expression and in vivo promoter binding, evaluated in Usf1-and Usf2-null mice, revealed differences between testis and ovary in their response to loss of either USF protein [109] . Thus, in testis, Fshr expression was unchanged by either Usf1 or Usf2 deletion and showed compensatory increases in promoter-bound USF homodimers [71, 109] . In contrast, ovarian Fshr expression declined in both, and compensatory change in homodimer binding was not indicated. Additional studies of the Fshr promoter in Sertoli cells showed that USF binding to the E box increases during differentiation and decreases, together with promoter activity, upon FSH treatment [71, 110, 111] . The predicted mediator of these FSH-induced changes is the inhibitor of DNA binding/differentiation protein, ID2, which increases with FSH treatment and inhibits both E box binding and promoter activity (Fig. 1B) .
Despite numerous studies on the FSHR/Fshr promoter, no mechanism has evolved to explain the gene's remarkable cellspecific expression. This deficiency in promoter specificity was also demonstrated by studies that evaluated 16 distinct transgenic mouse lines for cell-specific expression of reporters directed by either 5.0 kbp or 143 bp (eight mouse lines each) of rat Fshr promoter sequence, none of which showed Sertoli or granulosa cell expression [91] . Similar findings were reported for 1.5 kbp of the human promoter [112] . The recognition that sequences beyond the 5.0 kbp promoter were required for expression, together with emerging data on regulatory elements that act from distal positions, led to studies using yeast artificial chromosomes (YACs) as transgenes to define the region required for FSHR/Fshr specificity. The absent transgene expression in Sertoli and granulosa cells of mice carrying a YAC with the entire rat Fshr gene, plus bordering sequences stretching more than 50 kbp 5 0 and 30 kbp 3 0 , further supports involvement of distal regulation and suggests regulatory regions extend well beyond the gene itself [113] . 
FSHR: PROMOTER AND BEYOND
With the evidence that proper expression of FSHR/Fshr requires contributions from regulatory elements located outside the promoter region, most likely at significant distances, the challenge became identifying these sites within a vast amount of potential sequence. Initially, with only a small amount of available sequence, this was tackled using conventional DNase I hypersensitivity mapping to identify regions of accessible chromatin and, thus, potential sites of regulatory importance [114] . This revealed four hypersensitive sites located within a 45-kbp region surrounding the first exon, three of which showed significant sequence conservation, a predictive feature of important regulatory elements [114] . One of these, DHS#3, was located approximately 4 kb downstream in intron 1 and showed much greater sensitivity to DNase I in nonexpressing cells (myoid) than in expressing cells (Sertoli), suggesting an association with gene silencing (Fig. 1) . Further functional characterization, using transient transfections and in vitro and in vivo binding assays, revealed important elements that attenuated gene expression and their cognate binding proteins, octamer-binding protein 1 (POU2F1), GATA4, and GATA1. The studies also implicated POU2F1 in selective binding to this element in order to maintain its silent state in nonexpressing cells [114] . Whereas the approach proved to be a valid means to identify important regulatory elements, it was evident that scanning extensive regions of the genome without better knowledge of its DNA content or genomic landscape was impractical. This has since been remedied by the infusion of genomics data that brought not only new sequence information but also a wealth of insight regarding the FSHR/Fshr gene and it residing landscape.
THE FSHR GENE
The initial characterization of the FSHR gene in 1992 revealed a pronounced structural similarity to the LHCGR/ Lhcgr gene, which suggested that the two evolved through duplication of a common ancestral gene [115] . Similarities between FSHR/Fshr and LHCGR/Lhcgr and the genes for other GPCRs also suggested the predecessor for FSHR/Fshr and LHCGR/Lhcgr was formed by combining a common GPCR ancestral gene. The ancestor for these genes presumably arose by encoding the characteristic transmembrane and intracellular domains, with multiple repeated exons derived from tandem duplications of a module for a leucine-rich motif, a featured attribute of the extracellular domain of glycoprotein hormone receptors [115] . Formation of the gonadotropin receptor genes through tandem duplication of an ancestral gene was further substantiated by recent genomics data showing they are arranged in tandem on chromosomes from nearly all annotated Tetrapoda genomes [115] [116] [117] . The two ancestral descendents, FSHR/Fshr and LHCGR/Lhcgr, differ by one exon (10 for FSHR/Fshr and 11 for LHCGR/Lhcgr), but the coding scheme is largely the same, with the carboxyterminal, transmembrane-intracellular domain encoded by the last exon and the amino-terminal, extracellular domain encoded by all preceding exons [115, 118, 119] . Exons that partition the receptors' extracellular domains also share a repeated structure that delineates seven of the leucine-rich motifs into exons 2-8 and two into exon 9 (Fig. 2) .
Despite having known the structure of FSHR/Fshr for nearly two decades, accurate knowledge regarding its size or chromosome habitat was not available until the various genome-sequencing projects greatly expanded the available sequence data. Now, FSHR/Fshr chromosome locations and annotated sequences are available for more than 40 vertebrate species through the University of California, Santa Cruz (UCSC) Genome Browser (http://genome.ucsc.edu/) and similar websites. In the human, rat, and mouse, the FSHR/ Fshr gene is located on chromosome 2, 6, and 17, respectively, and spans roughly 200 kb, a size much larger than originally predicted [92, 115, [120] [121] [122] (Fig. 2) . This wealth of sequence information also disclosed several defining features of FSHR/ Fshr and its surrounding neighborhood that indicate its associated regulatory environment is strongly influenced by evolutionary constraints that retain regulatory sequences directing distally located genes [113, 114] . This includes the tandem placement of FSHR/Fshr between it closest 5 0 neighbor, NRXN1/Nrxn1, which encodes the synaptic neuronal adhesion protein NEUREXIN 1, and its closest 3 0 neighbor, LHCGR/Lhcgr, the gene encoding the LHR, to form a highly conserved syntenic block, a feature that has been identified by several studies as indicating evolutionary constraints intended to preserve the relative positions between noncoding sequences and their target genes [114, [123] [124] [125] .
The genomic relationship between FSHR/Fshr and LHCGR/ Lhcgr, when examined together with their similar expression profiles and functions in gonadotropin signaling, raises the intriguing possibility that the function of one or both genes depends on their relative positions. In considering potential mechanisms, a link between transcriptional regulation and the shared synteny can be readily conceived if expression of FSHR/Fshr and/or LHCGR/Lhcgr depends on regulatory sequences that would be lost if the genes separated. This implies the sequences are either 1) required for expression of one gene and reside within the locus defined by the other (gene plus regulatory domain) or 2) required by both genes (i.e., identical or overlapping sites), with function depending on their position relative to FSHR/Fshr and LHCGR/Lhcgr. The second mechanism can be expanded to include the use of sequences for concurrent gene regulation, which for coregulation of FSHR/Fshr and LHCGR/Lhcgr activity is limited to granulosa cells of growing follicles, the only cells that express both genes. So, despite similar gonad-specific expression profiles, the receptors are largely confined to distinct cell types, where any simultaneous use of a regulatory sequence will require opposite transcriptional effects on the two genes. Thus, most gonadotropin-responsive cells do not coexpress FSHR/ Fshr and LHCGR/Lhcgr: FSH response is restricted to Sertoli cells of the testis and granulosa cells of the ovary, and LH response is confined to testicular Leydig cells and ovarian theca, maturing granulosa, and luteal cells [50, [126] [127] [128] [129] .
To date, no regulatory elements shared by FSHR/Fshr and LHCGR/Lhcgr or located within the other's defined locus have been identified. However, our knowledge of their transcription is represented almost entirely by promoter characteristics and, therefore, is insufficient to conclude the elements do not exist. Regardless, promoter characteristics do suggest divergent regulation, because they differ significantly with respect to sequence, identified regulatory elements, and activity in transgenic mice (i.e., LHCGR/Lhcgr, but not FSHR/Fshr, promoter directs cell-specific expression in vivo) [43, 87, 90, 93, 113, 115, [130] [131] [132] [133] [134] [135] . On the other hand, a few common promoter features are worth noting. First is the core structure, which in both lacks a TATA box and has multiple transcription initiation sites within a region similar to an initiator element [87, 115, 119, 136, 137] . Second is the ubiquitous nature of each promoter's main functional element(s), which depends largely on nonspecific, widely expressed, but distinct transcription factors (LHCGR/Lhcgr with two GC-rich sequences that bind SP1 and SP3 and FSHR/Fshr with a single E box bound by USF1 and USF2) [87, 91, 135, 138] . These similarities may reflect the common ancestry and/or association 10 GEORGE ET AL.
FIG. 3. Annotated region of human FSHR and neighboring genes NRXN1
and LHCGR from the UCSC Genome Browser (http://genome.ucsc.edu/). With human as the reference genome, noncoding ECRs (top) were selected for their potential regulatory activity using sequence conservation, both vertebrate consensus and net alignment (chicken as the target), and 7X regulatory potential. Vertebrate consensus representing alignments of 44 vertebrate species were generated using multiz and other tools and measurements of evolutionary conservation as determined by phastCons and phyloP [183, 184] . The 7X regulatory potential track represents scores computed from the human, chimpanzee, macaque, mouse, rat, dog, and cow by comparing short alignment pattern frequencies between known regulatory elements and neutral DNA [144, [172] [173] [174] [175] . The net alignment tracks show the best mouse/human or chicken/human chains for every part of the human genome, with ungapped alignments represented by boxes and gaps by lines. Annotated sequences are from the chicken May 2006 (WUGSC 2.1/galGal3) (galGal3) assembly, mouse July 2007 (NCBI37/mm9) (mm9) assembly, and human March 2006 (NCBI36/hg18) assembly.
FSHR: PROMOTER AND BEYOND
via an undisclosed fundamental mechanism, but the predominant promoter characteristics emphasize functional divergence of key regulatory features that highlight the promoter for LHCGR/Lhcgr and distal regulatory sites for FSHR/Fshr. Another notable feature is the large intergenic distances between FSHR/Fshr and its neighbors, which span more than 750 kbp on its 5 0 side and 200 kbp on its 3 0 side [114] . The uninhabited region between NRXN1/Nrxn1 and FSHR/Fshr is characteristic of a gene desert, or long genomic stretch devoid of protein-coding sequences or other obvious biological functions. Such regions, when located within a conserved syntenic block, are associated with areas of enhanced sequence conservation, suggesting the content was under evolutionary pressure to retain functional and contextual information of resident elements [123, 139, 140] . Whereas evidence shows that not all gene deserts have measurable activity, numerous risk loci and regulatory elements are documented within these regions, confirming their importance to the genome [141] [142] [143] . Comparative sequence analysis has been consistently used in genome-wide studies to evaluate evolutionary constraint as a means to understand genome structure, biological function, and evolution [144] . The initial whole-genome sequence comparisons between mouse and human provided considerable insight and estimated that 5% of the human genome was conserved over 70-100 million years [139, [144] [145] [146] [147] [148] . What was remarkable in this finding was that only a third of the conserved sequences was located in coding regions. Thus, the genome's noncoding sector represents the largest portion under evolutionary selection, which suggests considerable functional information is within conserved noncoding sequences (i.e., evolutionary conserved regions [ECRs]) [144, 149] .
Expansion of genome sequence data and species representation added significantly to the power of cross-species sequence comparison, the genomic landscape, and sites of potential biological functions. These breakthroughs have led to identification of many noncoding sequences involved in gene regulation, including enhancers, insulators, silencers, and matrix attachment regions [150] [151] [152] [153] [154] [155] [156] [157] . A connection between sequence conservation and regulatory sequences was nicely illustrated in a recent study that used ChIP with massively parallel sequencing to map DNA sites linked to p300, a coregulator for many transcription factors [158] . Results from mouse embryonic tissues (forebrain, midbrain, and limb) showed p300 to be highly enriched at sites containing conserved noncoding sequence and, of those evaluated, nearly all were functional. The study also demonstrated that most p300-associated sites/enhancers were located at least 10 kbp from a potential target gene, which suggests distal elements are commonly involved in transcriptional control. Direct evidence for long-distance gene regulation is found in numerous studies that demonstrate transcriptional effects from distant sequences on specific target genes, such as those for b-globin, interferongamma, SOX9, GATA3, fibroblast growth factor 4, interleukin 10, and CD69 [159] [160] [161] [162] . The significance of noncoding regulatory sequences to human disorders has also gained recognition with reports linking them to diseases and developmental disorders, as noted in cases of X-linked deafness, preaxial polydactyl, campomelic dysplasia, sex reversal, and postaxial polydactyly [143, [163] [164] [165] [166] . In the case of preaxial polydactyl, the reported mutation was located within a regulatory element approximately 1 Mbp from its target gene that emphasizes not only the remarkable linear distance in which the transcriptional signal passes but also the importance of nuclear architecture in positioning regions that collaborate in the transcriptional signal (for review, see [167] ).
THE SEARCH FOR NEW REGULATORY ELEMENTS
The search for new regulatory elements is clearly facilitated by predictions based on sequence conservation. However, the evidence is also clear that sequence conservation does not detect all regulatory elements, nor does it provide any assurance that the predicted sites are functional. Thus, sequence conservation is most effective when used in conjunction with other corroborating techniques, particularly ones that can assess chromatin changes linked to transcriptional activity [149, 152, 162, [168] [169] [170] [171] . In studies to identify regulatory sequences that direct FSHR/Fshr transcription, results from transgenic and promoter studies shifted the experimental focus away from the promoter to the region encompassing all of FSHR/Fshr and its adjoining intergenic regions, which required a new set of tools and resources that fortunately evolved from the collection of genome sequences and efforts to understand their content. Initial reports on the FSHR/Fshr conservation profile compared human and rat sequences by direct pairwise comparison and analysis of precompiled Limited Area Global Alignment of Nucleotides (LAGAN) alignments through the web-based VISTA genome browser [114] . This revealed more than 150 conserved sites, which, when matched together with DNase I hypersensitivity data, was instrumental in the identification of an important silencing region in the first intron (discussed above). However, it was also evident that greater constraints were required to improve functional prediction. Therefore, once more distant genomes (e.g., chicken) were available and included in computations, ECRs having greater predictive power could be distinguished, and seven of the most conserved were selected for functional testing by transient transfection [113] . With continuous enhancements in genome data and resources that improve regulatory element prediction, the number of selected sites has grown to more than 20, a number that includes the original seven ECRs. These sequences were identified using the human genome and the UCSC Genome Browser (http://genome.ucsc.edu/) to reveal highly conserved (vertebrate consensus and net alignment with chicken as the target), noncoding sequences with a significant regulatory potential score (7X regulatory potential) [144, [172] [173] [174] [175] [176] ). Figure 3 provides an example of the FSHR locus spanning from LHCGR to NRXN1 that was modified from the UCSC Genome Browser results to show the top predicted sites (marked ECRs) for FSHR/Fshr regulatory sequences and the key features used in their selection.
SUMMARY
In summary, the evidence to date shows that sequences directing FSHR/Fshr expression lie far from the start of transcription in a regulatory environment without defined boundaries, which complicates their detection using standard molecular approaches. Computational genomics has helped narrow the search, but limitations resulting from false positives and undetected sequences caution its use without additional methods to substantiate the data [177] . Fortunately, many technologies have adapted to the influx of sequence data by developing high-throughput and genomewide strategies. Two such strategies offer considerable promise for regulatory element identification and for the FSHR/Fshr transcriptional mechanism being within reach. Both strategies reveal chromatin signatures featured in regulatory sequences: One identifies sequences bound to modified histones linked to transcriptional activity by ChIP, and the other identifies open regions of chromatin, similar to DNase I hypersensitivity, by formaldehyde-associated identification of regulatory ele-12 GEORGE ET AL. ments. [178, 179] . Implementation of such strategies together with comparative genomics will significantly enhance the probability of relevant sequence identification and the mechanistic understanding of the regulatory landscape. When combined with high-throughput strategies, such as DNaseChIP, high-density tiling arrays and next generation sequencing, to canvass the genome without the bias of conservation, additional insight is likely regarding mechanisms that employ nonconserved regulatory elements and possible contributions to species-specific regulatory features [180] [181] [182] .
